CareDx builds and sells diagnostics (CDNA) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving CareDx builds and sells diagnostics (CDNA) right now is Testing-volume growth: Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. Revenue (TTM) is ~$413M. If that keeps playing out, the setup is favourable; the risk to it is reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. No one can predict where CDNA trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive CareDx builds and sells diagnostics (CDNA) higher?
1. Testing-volume growth
Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. Continued adoption of AlloSure across kidney and heart transplant surveillance is the primary top-line driver.
2. Return to profitability
After years of losses, CareDx delivered positive net income and EPS in Q1 2026 and raised adjusted EBITDA guidance to roughly $43 million to $57 million for the year. If cost discipline holds, the shift from cash burn toward sustained profit is a meaningful re-rating catalyst.
3. Portfolio reshaping
Management is buying Naveris, an HPV-driven solid-tumor diagnostics business (about $34 million in 2025 revenue with 30% to 40% growth potential), while divesting Lab Products for roughly $170 million upfront. This tightens focus on high-value clinical testing and adds an oncology adjacency.
4. Integrated transplant platform
Beyond individual tests, CareDx bundles digital workflow tools, pharmacy services, and patient management, aiming to embed itself deeply in transplant-center operations. This platform breadth is intended to widen its moat against single-test competitors.
What could weigh on CDNA?
Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.
Where CDNA trades today
A forecast starts from where the stock actually is. These are CDNA's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for CDNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a CDNA forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the CDNA guide and whether CDNA is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the CDNA outlook
The bottom line: what is driving CareDx builds and sells diagnostics (CDNA) is Testing-volume growth, with revenue (ttm) at ~$413M. If that keeps playing out the setup is favourable; the risk is reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. No one can predict the price, so treat any CDNA forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around CDNA with Walnut
Use CareDx builds and sells diagnostics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for CareDx builds and sells diagnostics (CDNA)?
+
No one can reliably predict where CDNA will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push CareDx builds and sells diagnostics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive CDNA higher?
+
The main growth drivers are Testing-volume growth; Return to profitability; Portfolio reshaping. Whether they play out is the real question, not a guaranteed path.
What are the risks to CDNA?
+
Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.
Will CDNA stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. CareDx builds and sells diagnostics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is CDNA a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the CDNA "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is CareDx growing?
+
Growth reaccelerated sharply in early 2026, with Q1 revenue up about 39% year over year and testing volume up roughly 17%. Full-year 2026 revenue guidance of about $447 million to $465 million implies continued strong double-digit growth.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.